Research programme: cancer radiopharmaceuticals - Progenics Pharmaceuticals

Drug Profile

Research programme: cancer radiopharmaceuticals - Progenics Pharmaceuticals

Alternative Names: 131-I-MIP-1375; 99mTc-MIP-1340; 99mTc-MIP-1407; I-131-MIP-1466; MIP-1340; MIP-1375; MIP-1407; MIP-1466; MIP-1555; MIP-1558; MIP-220; Radiolabelled SSTR2 agonist and antagonist peptides - Progenics; Tc-99m-PSMA inhibitors - Progenics

Latest Information Update: 04 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Diagnostic agents; Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Prostate cancer

Most Recent Events

  • 15 Mar 2013 PSMA-targeting small-molecule therapeutics are still in preclinical trials for Prostate cancer in USA
  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 13 Jun 2011 Pharmacodynamics, pharmacokinetics & adverse events data from preclinical trials in Prostate cancer and Neuroendocrine tumours presented at the 2011 Annual Meeting of the Society of Nuclear Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top